Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding
specificity to CD20. It was the first therapeutic antibody approved for oncology patients and …

Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase δ
and γ (PI3K-δ, γ) being developed for treatment of hematologic malignancies. PI3K-δ, γ …

Background Deletion of chromosome 17p (del [17p]) in patients with chronic lymphocytic
leukaemia confers very poor prognosis when treated with standard chemo-immunotherapy …

Abstract Disease Overview Chronic lymphocytic leukemia (CLL) is the commonest leukemia
in western countries. The disease typically occurs in elderly patients and has a highly …

Background In patients with chronic lymphoid leukemia (CLL) or small lymphocytic
lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic …

Background Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically
significant coexisting medical conditions are less able to undergo standard chemotherapy …

Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in
few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell …

Importance The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with
chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy with this drug and …

In a phase 1 trial, idelalisib (GS-1101, CAL-101), a selective inhibitor of the lipid kinase
PI3Kδ, was evaluated in 54 patients with relapsed/refractory chronic lymphocytic leukemia …